Denali Therapeutics Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Departure of Directors or Certain Officers
Marc Tessier-Lavigne, our co-founder and a Board member, has recently informed us of his intention to step down from the Board effective September 1, 2025 to focus on his increased commitments as CEO and Chairman of Xaira Therapeutics, Inc. The Board extends its gratitude to Marc for his significant contributions to Denali over the past decade. We wish him and Xaira continued success.
Securities Trading Plans of Directors and Executive Officers
No officers or directors, as defined in Rule 16a-1(f), adopted and/orterminated of a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the second quarter ended June 30, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.